noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

City of El Paso, TX

City Parks and Recreation to Celebrate International Women’s Month at[...]
City of El Paso, TX

El Paso Zoo and Botanical Gardens Brings Back Summer Camps Full of Wild[...]
City of El Paso, TX

City Parks and Recreation Announces Easter Egg-Stravaganza Carnivals[...]

Healthcare

Kura Oncology Inc.

12/02/2025 | Press release | Distributed by Public on 12/02/2025 07:10

Material Event (Form 8-K)

Item 8.01

Other Events.

On December 2, 2025, Kura Oncology, Inc. (the "Company") announced the first U.S. commercial sale of KOMZIFTI^™ (ziftomenib) has been completed. Under the Company's collaboration and license agreement with Kyowa Kirin Co., Ltd. and Kyowa Kirin, Inc. (together, "Kyowa Kirin"), this milestone triggers a $135 million payment from Kyowa Kirin to the Company, which the Company expects to receive prior to year-end.KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025.

Kura Oncology Inc. published this content on December 02, 2025, and is solely responsible for the information contained herein. Distributed via EDGAR on December 02, 2025 at 13:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]